Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share from the same period last year.
Gilead Highlights Kite’s Tecartus CAR T-Cell Therapy Data In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial
-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months --
